Skip to main content
Clinical Trials/NCT03120013
NCT03120013
Completed
Not Applicable

Rehabilitative Trial With Cerebello-Spinal tDCS for the Treatment of Neurodegenerative Ataxia

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia1 site in 1 country21 target enrollmentFebruary 6, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ataxia, Cerebellar
Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Enrollment
21
Locations
1
Primary Endpoint
Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Neurodegenerative cerebellar ataxias represent a group of disabling disorders for which we currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS can improve symptoms in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.

Detailed Description

Neurodegenerative cerebellar ataxias represent a heterogeneous group of disabling disorders in which progressive ataxia of gait, limb dysmetria, oculomotor deficits, dysarthria and kinetic tremor are the prominent clinical manifestations. Both the hereditary and sporadic forms usually present in young adulthood, and are characterized by atrophy of cerebellar or brainstem structures. Currently, cerebellar ataxia lack effective disease-modifying therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. The present randomized, double-blind, sham-controlled study will investigate whether a two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS can improve symptoms in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term. Subjects will be randomized in two groups, one receiving a 10 day (5 days/week for 2 weeks) treatment with anodal cerebellar and cathodal spinal tDCS and the other receiving sham stimulation with identical parameters. After the intervention, patients will be reassessed with a clinical and neurophysiological evaluation at 2 weeks, 1 months and 3 month after treatment.

Registry
clinicaltrials.gov
Start Date
February 6, 2017
End Date
December 1, 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Barbara Borroni

Professor

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Eligibility Criteria

Inclusion Criteria

  • Patients with a cerebellar syndrome and quantifiable cerebellar atrophy

Exclusion Criteria

  • Severe head trauma in the past
  • History of seizures
  • History of ischemic stroke or hemorrhage
  • Pacemaker
  • Metal implants in the head/neck region
  • Severe comorbidity
  • Intake of illegal drugs
  • Pregnancy

Outcomes

Primary Outcomes

Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline

Time Frame: Baseline - 2 weeks

International Cooperative Ataxia Rating Scale (ICARS): semi-quantitative 100-point scale, yielding a total score of 0 (no ataxia) to 100 (most severe ataxia).

Change in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline

Time Frame: Baseline - 2 weeks

Scale for the Assessment and Rating of Ataxia (SARA): 8-item performance based scale, yielding a total score of 0 (no ataxia) to 40 (most severe ataxia).

Secondary Outcomes

  • Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline(Baseline - 2 weeks - 1 month - 3 months)
  • Change in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline(Baseline - 2 weeks - 1 month - 3 months)
  • Change in the 8-Meter Walking Time (8MW) Score From Baseline(Baseline - 2 weeks - 1 month - 3 months)
  • Change in the Short-Form Health Survey 36 (SF36) Score From Baseline(Baseline - 2 weeks - 1 month - 3 months)
  • Change in the 9 Hole Peg Test (9HPT) Score From Baseline(Baseline - 2 weeks - 1 month - 3 months)
  • Change in Cerebellar Brain Inhibition (CBI) Measurements From Baseline(Baseline - 2 weeks - 1 month - 3 months)

Study Sites (1)

Loading locations...

Similar Trials